首页> 外文期刊>International Journal of Molecular Sciences >The Efficacy of the Quorum Sensing Inhibitor FS8 and Tigecycline in Preventing Prosthesis Biofilm in an Animal Model of Staphylococcal Infection
【24h】

The Efficacy of the Quorum Sensing Inhibitor FS8 and Tigecycline in Preventing Prosthesis Biofilm in an Animal Model of Staphylococcal Infection

机译:群体感应抑制剂FS8和替加环素在葡萄球菌感染动物模型中预防假体生物膜的功效

获取原文
           

摘要

We investigated the efficacy of tigecycline and FS8, alone or combined, in preventing prosthesis biofilm in a rat model of staphylococcal vascular graft infection. Graft infections were established in the back subcutaneous tissue of adult male Wistar rats by implantation of Dacron prostheses followed by topical inoculation with 2 × 107 colony-forming units of Staphylococcus aureus, strain Smith diffuse. The study included a control group, a contaminated group that did not receive any antibiotic prophylaxis, and three contaminated groups that received: (i) intraperitoneal tigecycline, (ii) FS8-soaked graft, and (iii) tigecycline plus FS8-soaked graft, respectively. Each group included 15 animals. The infection burden was evaluated by using sonication and quantitative agar culture. Moreover, an in vitro binding-study was performed to quantify the how much FS8 was coated to the surface of the prosthesis. Tigecycline, combined with FS8, against the adherent bacteria showed MICs (2.00 mg/L) and MBCs (4.00 mg/L) four-fold lower with respect to tigecycline alone in in vitro studies. The rat groups treated with tigecycline showed the lowest bacterial numbers (4.4 × 104 ± 1.2 × 104 CFU/mL). The FS8-treated group showed a good activity and significant differences compared to control group with bacterial numbers of 6.8 × 104 ± 2.0 × 104 CFU/mL. A stronger inhibition of bacterial growth was observed in rats treated with a combined FS8 and tigecycline therapy than in those that were singly treated with bacterial numbers of 101 CFU/mL graft. In conclusion, the ability to affect biofilm formation as well, its property to be an antibiotic enhancer suggests FS8 as alternative or additional agent to use in conjunction with conventional antimicrobial for prevention of staphylococcal biofilm related infection.
机译:我们研究了替加环素和FS8单独或联合使用在预防葡萄球菌血管移植物感染的大鼠模型中的修复体生物膜方面的功效。成年Wistar大鼠的背部皮下组织移植感染,方法是植入Dacron假体,然后局部接种2×10 7 金黄色葡萄球菌菌落形成单位,Smith扩散株。该研究包括一个对照组,一个未接受任何抗生素预防的污染组和三个污染组,分别接受:(i)腹膜内替加环素,(ii)FS8浸泡的移植物和(iii)tigecycline加上FS8浸泡的移植物,分别。每组包括15只动物。通过超声处理和定量琼脂培养评估感染负担。此外,进行了体外结合研究以量化在假体表面上涂覆了多少FS8。在体外研究中,与单独的替加环素相比,替加环素与FS8结合对粘附细菌的抑制作用显示MIC(2.00 mg / L)和MBC(4.00 mg / L)降低了四倍。替加环素治疗的大鼠组细菌数最低(4.4×10 4 ±1.2×10 4 CFU / mL)。 FS8处理组与对照组相比,表现出良好的活性和显着性差异,细菌数为6.8×10 4 ±2.0×10 4 CFU / mL。与单独用细菌数量为10 1 CFU / mL移植的单药治疗的大鼠相比,用FS8和替加环素联合治疗的大鼠对细菌生长的抑制作用更强。总之,影响生物膜形成的能力以及其作为抗生素增强剂的性质表明,FS8作为替代或附加药剂可与常规抗微生物剂一起用于预防葡萄球菌生物膜相关感染。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号